TOVX Latest Press Releases

-- July 7, 2026 --

Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma Globe Newswire 8:00 AM

-- June 11, 2026 --

Theriva Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research Globe Newswire 8:00 AM

-- May 5, 2026 --

Theriva Biologics Reports First Quarter 2026 Operational Highlights and Financial Results Globe Newswire 4:30 PM

-- April 17, 2026 --

Theriva Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting Globe Newswire 4:05 PM

-- March 23, 2026 --

Theriva Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma Globe Newswire 8:00 AM

-- March 12, 2026 --

Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software